Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence

被引:44
作者
Akaishi, Tetsuya [1 ,2 ]
Nakashima, Ichiro [3 ]
Takahashi, Toshiyuki [1 ,4 ]
Abe, Michiaki [1 ,2 ]
Ishii, Tadashi [2 ]
Aoki, Masashi [2 ]
机构
[1] Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi, Japan
[2] Tohoku Univ Hosp, Dept Educ & Support Reg Med, Sendai, Miyagi, Japan
[3] Tohoku Med & Pharmaceut Univ, Dept Neurol, Sendai, Miyagi, Japan
[4] Natl Hosp Org Yonezawa Natl Hosp, Dept Neurol, Yonezawa, Yamagata, Japan
关键词
DIAGNOSTIC-CRITERIA; AQUAPORIN-4; ANTIBODY; THERAPY; NMO;
D O I
10.1212/NXI.0000000000000640
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveThe aim of this study was to elucidate the characteristics of clinical attacks in neuromyelitis optica spectrum disorders (NMOSDs) with positive serum anti-aquaporin-4 antibody. Both the timing and sequential pattern of clinical types were analyzed.MethodsA total of 69 patients with NMOSD were enrolled in this study, all of whom were treated at a single university hospital. All data regarding the clinical attacks (including types and date) together with other clinical information were collected.ResultsAnalysis of clinical attacks from the enrolled patients showed that there were 2 distributional patterns of attack occurrence in each patient: (1) "clustered" occurrences, which occurred within 12 months from the previous attack, and (2) "nonclustered" intermittent occurrences, which occurred >= 12 months after the previous attack. These occurrences were regardless of the duration from the onset. During the "clustered" period, clinical attacks were more likely to show a similar clinical manifestation, such as optic neuritis or myelitis. After entering the "nonclustered" intermittent period, the relapses were of random clinical type, regardless of the previous clinical manifestation.ConclusionsPatients with NMOSD showed mixed periods of "clustered" occurrence with frequent attacks presenting with similar manifestations and "nonclustered" intermittent periods with sparse relapses. Approximately half of the relapses occurred during the "clustered" period within 12 months of the last clinical attack. Clinicians should pay special attention to whether the patients are presently in the "clustered" or "nonclustered" period to decide optimal relapse-preventive strategies.
引用
收藏
页数:8
相关论文
共 22 条
[1]   Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study [J].
Agius, Mark A. ;
Klodowska-Duda, Gabriela ;
Maciejowski, Maciej ;
Potemkowski, Andrzej ;
Li, Jing ;
Patra, Kaushik ;
Wesley, Jacob ;
Madani, Soraya ;
Barron, Gerard ;
Katz, Eliezer ;
Flor, Armando .
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) :235-245
[2]   Efficiency of antibody therapy in demyelinating diseases [J].
Akaishi, Tetsuya ;
Nakashima, Ichiro .
INTERNATIONAL IMMUNOLOGY, 2017, 29 (07) :327-335
[3]   Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis [J].
Borisow, Nadja ;
Mori, Masahiro ;
Kuwabara, Satoshi ;
Scheel, Michael ;
Paul, Friedemann .
FRONTIERS IN NEUROLOGY, 2018, 9
[4]   Placebo-controlled study in neuromyelitis optica-Ethical and design considerations [J].
Cree, Bruce A. C. ;
Bennett, Jeffrey L. ;
Sheehan, Mark ;
Cohen, Jeffrey ;
Hartung, Hans-Peter ;
Aktas, Orhan ;
Kim, Ho Jin ;
Paul, Friedemann ;
Pittock, Sean ;
Weinshenker, Brian ;
Wingerchuk, Dean ;
Fujihara, Kazuo ;
Cutter, Gary ;
Patra, Kaushik ;
Flor, Armando ;
Barron, Gerard ;
Madani, Soraya ;
Ratchford, John N. ;
Katz, Eliezer .
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (07) :862-872
[5]  
Jacob A, 2009, ARCH NEUROL-CHICAGO, V66, P1128, DOI 10.1001/archneurol.2009.175
[6]   Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic [J].
Kessler, Remi A. ;
Mealy, Maureen A. ;
Levy, Michael .
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2016, 18 (01) :1-15
[7]   Racial differences in neuromyelitis optica spectrum disorder [J].
Kim, Su-Hyun ;
Mealy, Maureen A. ;
Levy, Michael ;
Schmidt, Felix ;
Ruprecht, Klemens ;
Paul, Friedemann ;
Ringelstein, Marius ;
Aktas, Orhan ;
Hartung, Hans-Peter ;
Asgari, Nasrin ;
Tsz-Ching, Jessica Li ;
Siritho, Sasitorn ;
Prayoonwiwat, Naraporn ;
Shin, Hyun-June ;
Hyun, Jae-Won ;
Han, Mira ;
Leite, Maria Isabel ;
Palace, Jacqueline ;
Kim, Ho Jin .
NEUROLOGY, 2018, 91 (22) :E2089-E2099
[8]   Treatment of neuromyelitis optica: Review and recommendations [J].
Kimbrough, Dorlan J. ;
Fujihara, Kazuo ;
Jacob, Anu ;
Lana-Peixoto, Marco A. ;
Leite, Maria Isabel ;
Levy, Michael ;
Marignier, Romain ;
Nakashima, Ichiro ;
Palace, Jacqueline ;
de Seze, Jerome ;
Stuve, Olaf ;
Tenembaum, Silvia N. ;
Traboulsee, Anthony ;
Waubant, Emmanuelle ;
Weinshenker, Brian G. ;
Wingerchuk, Dean M. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2012, 1 (04) :180-187
[9]   Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders [J].
Kleiter, Ingo ;
Gold, Ralf .
NEUROTHERAPEUTICS, 2016, 13 (01) :70-83
[10]   Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future [J].
Lin, Jie ;
Xue, Binbin ;
Li, Xiang ;
Xia, Junhui .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2017, 127 (08) :735-744